Announced

atai Life to merge with Beckley Psytech.

Synopsis

atai Life, a clinical-stage biopharmaceutical company, agreed to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company. Financial terms were not disclosed. “The strategic combination marks a transformational moment, solidifying us as a leader in rapid-acting and accessible psychedelic treatments for mental health conditions with a pipeline of potential first-in-class and best-in-class assets. With a unified vision and a synergistic pipeline, we believe we are well-positioned to unlock the strategic value of our clinical development programs for both patients and shareholders. Together, we plan to move confidently towards our goal of bringing innovative interventional psychiatry therapies to patients in need of new treatments,” Srinivas Rao, atai CEO and Co-Founder.

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Sort

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

All rights reserved. Copyright © 2025 Datasite